Healthy brain (bottom) versus brain of a donor with Alzheimer’s disease. Notable is the “shrink” that has occurred in Alzheimer’s disease; the brain was decreased in size. (Photo credit: Wikipedia)
“If these results are replicated in Alzheimer’s disease patients, it would open up a promising avenue of treatment of this devastating neurodegenerative disease.”
Buphenyl, an FDA-approved medication for hyperammonemia, may protect memory and prevent the progression of Alzheimer’s disease. Hyperammonemia is a life-threatening condition that can affect patients at any age. It is caused by abnormal, high levels of ammonia in the blood.
Studies in mice with Alzheimer’s disease (AD) have shown that sodium phenylbutyrate, known as Buphenyl, successfully increases factors for neuronal growth and protects learning and memory, according to neurological researchers at the Rush University Medical Center.
Results from the National Institutes of Health funded study, recently were published in the Journal of Biological Chemistry.
“Understanding how the disease works is important to developing effective drugs that protect the brain and stop the progression of Alzheimer’s disease,” said Kalipada Pahan, PhD, the Floyd A. Davis professor of neurology at Rush and lead investigator of this study.
A family of proteins known as neurotrophic factors help in survival and function of neurons. Past research indicates that these proteins are drastically decreased in the brain of patients with Alzheimer’s disease (AD).
“Neurotrophic factor proteins could be increased in the brain by direct injection or gene delivery,” said Pahan. “However, using an oral medication to increase the level of these protein may be the best clinical option and a cost effective way to increase the level of these proteins directly in the brain.”
“Our study found that after oral feeding, Buphenyl enters into the brain, increases these beneficial proteins in the brain, protects neurons, and improves memory and learning in mice with AD-like pathology,” said Pahan.
In the brain of a patient with AD, two abnormal structures called plaques and tangles are prime suspects in damaging and killing nerve cells. While neurons die, other brain cells like astroglia do not die.
The study findings indicate that Buphenyl increases neurotrophic factors from astroglia. Buphenyl stimulates memory-related protein CREB (cyclic AMP response element-binding protein) using another protein known as Protein Kinase C (PKC) and increases neurotrophic factors in the brain.
“Now we need to translate this finding to the clinic and test Buphenyl in Alzheimer’s disease patients,” said Pahan. “If these results are replicated in Alzheimer’s disease patients, it would open up a promising avenue of treatment of this devastating neurodegenerative disease.”
The Latest Bing News on:
Alzheimer’s
- Cold Sores and Shingles May Be Linked to Alzheimer’s, New Research Indicateson August 6, 2022 at 10:35 am
Could cold sores plus shingles lead to Alzheimer’s? New research from Tufts and Oxford universities adds to the growing evidence that they might—and how.
- 74-year-old man suffering from diabetes, Alzheimer's disease missing in Carsonon August 6, 2022 at 9:23 am
Authorities were asking for the public's help in finding a 74-year-old man suffering from Alzheimer's disease and diabetes who went missing in Carson. Daniel Peter Chavez, who also has high blood ...
- New research by MIT scientists shows how microglia contribute to Alzheimer’s diseaseon August 6, 2022 at 8:52 am
Microglia slow down neuron activity. The type of cells also results in the build-up of lipids. Treating them may be an effective cure for Alzheimer’s. Alzheimer’s is a debilitating disorder that is ...
- 81-year-old man with Alzheimer’s goes missing on his way to Family Dollar in Atlanta, police sayon August 6, 2022 at 4:37 am
Atlanta police are asking for your help locating a missing man with Alzheimer’s. Police issued a Mattie’s Call for 81-year-old Franklin Benton of Atlanta, Georgia. [DOWNLOAD: Free WSB-TV News app for ...
- Signs You Have Alzheimer's, According to Brain Expertson August 6, 2022 at 4:30 am
Alzheimer's disease is the most common form of dementia and affects as many as 5.8 million adults in the US. "One out of 3 cases of Alzheimer's may be preventable if that person does everything right, ...
- How varicella and herpes viruses may interact to trigger Alzheimer'son August 6, 2022 at 1:00 am
New research suggests that the interaction between two common viruses may be responsible for triggering the onset of Alzheimer’s disease.
- Herpes and shingles: Viral role in Alzheimer’s Disease revealedon August 5, 2022 at 2:01 pm
By using both laboratory-grown brain cells and a 3D brain model, the researchers examined whether VZV infection caused the accumulation of beta amyloid and abnormally phosphorylated tau (P-tau) and ...
- Program will address common questions about Alzheimer's diseaseon August 5, 2022 at 9:35 am
Pam Myers: "If you are having any issues discussed during the program, it is important to follow up with your physician." ...
- Alzheimer's Researchers Delve Into Data From Failed Crenezumab Trialon August 5, 2022 at 9:32 am
In the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease ( API ADAD) trial, crenezumab failed to slow or prevent decline over 5 to 8 years in cognitively healthy Colombian ...
- A Diabetes Drug Could Protect Against Alzheimer’s Disease, New Research Suggestson August 5, 2022 at 6:04 am
It turns out that drugs designed to treat type 2 diabetes may be able to do a lot more than just help regulate blood glucose levels. According to new research published in the jou ...
The Latest Google Headlines on:
Alzheimer’s
[/vc_column_text]
The Latest Bing News on:
Buphenyl
- Horizon Therapeutics PLCon August 2, 2022 at 5:00 pm
The orphan segment includes the medicines TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, UPLIZNA and also the Company’s research and development (R&D) programs.
- Horizon Therapeutics Public Limited Companyon August 1, 2022 at 5:00 pm
The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2% ...
- Horizon Therapeutics PLC Stock Quote HZNPon July 31, 2022 at 5:01 pm
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do ...
- Liminal (LMNL) Ends Development of Lead Candidate, Stock Downon July 22, 2022 at 9:34 am
Sodium Phenylbutyrate is marketed under the trade name Buphenyl by Ucyclyd Pharma and has been approved by the FDA for treating urea cycle disorders (UCD). Although there were no safety concerns ...
- Horizon Therapeutics PLCon June 14, 2022 at 5:00 pm
The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PEN ...
- BUPHENYL Side Effects by Likelihood and Severityon October 23, 2017 at 1:34 pm
an increased sodium level in the blood low amount of potassium in the blood high amount of uric acid in the blood ...
- Drugs & Medications A-Zon October 9, 2017 at 3:17 am
The display and use of drug information on this site is subject to express terms of use. By continuing to view the drug information, you agree to abide by such terms ...
- Medical Genetics Test Detailson June 15, 2016 at 4:31 am
Accordingly, treatment for UCD patients involves daily oral intake of ammonia scavenging drugs, including sodium phenylbutyrate (SPB) and/or glycerol phenylbutyrate (GPB) which go by the trade names ...